Cellular and gene therapy for major histocompatibility complex class II deficiency.
about
The class II transactivator (CIITA) is regulated by post-translational modification cross-talk between ERK1/2 phosphorylation, mono-ubiquitination and Lys63 ubiquitinationPhosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.
P2860
Cellular and gene therapy for major histocompatibility complex class II deficiency.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@ast
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@en
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@nl
type
label
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@ast
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@en
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@nl
prefLabel
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@ast
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@en
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@nl
P2860
P356
P1433
P1476
Cellular and gene therapy for major histocompatibility complex class II deficiency.
@en
P2093
Franck Matheux
Jean Villard
P2860
P304
P356
10.1152/NIPS.01462.2003
P577
2004-06-01T00:00:00Z